Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. 1993

P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
Ludwig Institute for Cancer Research, Brussels Branch, Belgium.

In order to define the antigens recognized by cytolytic T lymphocytes (CTLs) on autologous tumors, we derived tumor-specific CTL clones from autologous mixed lymphocyte tumor cell cultures. The gene coding for a tumor rejection antigen expressed on a melanoma was isolated by transfecting genomic DNA of the tumor into an antigen-loss variant of the melanoma. Transfectants were identified on the basis of their ability to stimulate tumor necrosis factor release by the CTL clone. The gene that transferred the expression of the antigen was named MAGE-1. It is a new gene, silent in normal tissues with the exception of testis, but expressed in several types of tumors. The antigen recognized by the CTL clone is a nonapeptide derived from the protein encoded by gene MAGE-1, and presented by the HLA class I molecule HLA-A1. Using two other antimelanoma CTL clones, we identified the tyrosinase gene as coding for an antigen presented by HLA-A2 on this type of tumors. The identification of these tumor rejection antigens open new possibilities for the specific immunotherapy of cancer.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005815 Genetic Code The meaning ascribed to the BASE SEQUENCE with respect to how it is translated into AMINO ACID SEQUENCE. The start, stop, and order of amino acids of a protein is specified by consecutive triplets of nucleotides called codons (CODON). Code, Genetic,Codes, Genetic,Genetic Codes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014442 Monophenol Monooxygenase An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1. Dopa Oxidase,Phenoloxidase,Tyrosinase,Cresolase,Phenol Oxidase,Phenoloxidase A,Phenoloxidase B,Monooxygenase, Monophenol,Oxidase, Dopa,Oxidase, Phenol
D015789 HLA-A2 Antigen A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family. HLA Class I Histocompatibility Antigen, A-2 alpha Chain,HLA-A2,Antigen, HLA-A2,HLA A2 Antigen,HLA Class I Histocompatibility Antigen, A 2 alpha Chain

Related Publications

P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
June 1995, Immunological reviews,
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
June 1997, Methods (San Diego, Calif.),
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
January 1997, Eye (London, England),
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
May 1993, International journal of cancer,
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
March 1996, The Journal of experimental medicine,
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
July 1995, Stem cells (Dayton, Ohio),
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
January 1987, Cell,
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
January 2019, Methods in molecular biology (Clifton, N.J.),
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
January 1994, Annual review of immunology,
P G Coulie, and P Weynants, and F Lehmann, and J Herman, and V Brichard, and T Wölfel, and A Van Pel, and E De Plaen, and F Brasseur, and T Boon
January 1997, International journal of clinical & laboratory research,
Copied contents to your clipboard!